Proteasome inhibition as a therapeutic strategy for hematologic malignancies.
about
The RBCC gene RFP2 (Leu5) encodes a novel transmembrane E3 ubiquitin ligase involved in ERADDrugging the cancer kinome: progress and challenges in developing personalized molecular cancer therapeuticsAntiprotease therapy in cancer: hot or not?Regulation of the proapoptotic factor Bax by Ku70-dependent deubiquitylation.Peptide and Peptide-Like Modulators of 20S Proteasome Enzymatic Activity in Cancer Cells
P2860
Proteasome inhibition as a therapeutic strategy for hematologic malignancies.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Proteasome inhibition as a therapeutic strategy for hematologic malignancies.
@ast
Proteasome inhibition as a therapeutic strategy for hematologic malignancies.
@en
type
label
Proteasome inhibition as a therapeutic strategy for hematologic malignancies.
@ast
Proteasome inhibition as a therapeutic strategy for hematologic malignancies.
@en
prefLabel
Proteasome inhibition as a therapeutic strategy for hematologic malignancies.
@ast
Proteasome inhibition as a therapeutic strategy for hematologic malignancies.
@en
P2093
P2860
P356
P1476
Proteasome inhibition as a therapeutic strategy for hematologic malignancies.
@en
P2093
Constantine S Mitsiades
Nicholas Mitsiades
Teru Hideshima
P2860
P304
P356
10.1586/14737140.5.3.465
P577
2005-06-01T00:00:00Z